Register for a live broadcast to learn more about TRODELVY (sacituzumab govitecan-hziy) with Dr. Hope S. Rugo

AE Management Could Affect Compliance in Breast Cancer Treatment

MADELINE KUIPER, MSN, RN, OCN
Tuesday, December 17, 2019


When patients with HER2-positive breast cancer know what kind of adverse events to look out for, they tend to have better communication with their healthcare team and, as a result, better compliance and outcomes, according to Madeline Kuiper, MSN, RN, OCN, an oncology nurse practitioner at UCLA.

Transcription

Unfortunately, there are side effects associated with HER2 therapies, as there are with multiple other types of treatments. But if you can explain that to a patient and help them look for and and understand potential side effects, and actually try to institute practices to mitigate those, patients tend to do much better on therapy, and tend to then commit to their therapy and stay on their therapy consistently. Then we can tend to get long-term therapy in compliance with that. Particularly, my setting is more of a metastatic setting. So I have patients who have been on HER2 therapies for 20 years. And they've done very well because [they're] great drugs, but also because we spend a lot of time going over potential side effects and how to manage them.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Related Videos
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.